Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01257308
First received: December 8, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted
  Purpose

We wants to analyse the EML4-ALK mutation rate in the patients who have non-small cell lung cancer.


Condition
Lung Cancer Patients

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients

Resource links provided by NLM:


Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 100
Study Start Date: August 2010
Estimated Study Completion Date: August 2013
  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Lung Cancer Patients

Criteria

Inclusion Criteria:

  • 20 or more than 20 years of age
  • The pathological diagnosis confirmed lung cancer
  • Patients have achieved pleural effusion, or surgical biopsy to obtain tumor tissue specimens
  • The patient had signed inform consent

Exclusion Criteria:

  • pleural effusion or tumor tissue can not be obtained
  • the patient is not suitable to join the research according to the judgement by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01257308

Locations
Taiwan
Taipei Medical University - WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Hsin-Gjin Eugene Liu Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Hsingjin Eugene Liu, MD PhD, Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier: NCT01257308     History of Changes
Other Study ID Numbers: 99047
Study First Received: December 8, 2010
Last Updated: December 8, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Pleural Effusion
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Pleural Diseases

ClinicalTrials.gov processed this record on October 02, 2014